(Total Views: 533)
Posted On: 10/25/2021 7:51:35 AM
Post# of 72447
Innovation Pharmaceuticals’ COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th
Brilacidin
WAKEFIELD, MA / October 25, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the Company anticipates reporting topline results the week of November 8th from its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The study data is presently blinded at the data management vendor, with final checks and approvals in progress.
Brilacidin
WAKEFIELD, MA / October 25, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the Company anticipates reporting topline results the week of November 8th from its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The study data is presently blinded at the data management vendor, with final checks and approvals in progress.
(0)
(0)
Ronald A Phillips
